Mechanism of action of anti-hypercholesterolemia drugs and their resistance

European Journal of Pharmacology

Volumn 741, Issue , 2014, Pages 156-170

  Tiwari, Vishvanath ^a   Khokhar, Manoj ^a  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

Author keywords

Anti hypercholesterolemia drugs; Fibrate resistance; Hypercholesterolemia; Statin resistance

Indexed keywords

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL; BINDING SITE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ACYL COENZYME A; ANIMALS; ANTICHOLESTEREMIC AGENTS; BINDING SITES; DRUG RESISTANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROTEIN STRUCTURE, SECONDARY;

EID: 84906962536     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.07.048     Document Type: Review

References (181)

1. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derre, L. Villeger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J.M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N.G. Seidah, and C. Boileau Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat. Genet. 34 2003 154 156
2. A.T. Al-Hinai, A. Al-Abri, H. Al-Dhuhli, K. Al-Waili, H. Al-Sabti, S. Al-Yaarubi, K. Al-Hashmi, Y. Banerjee, I. Al-Zakwani, and K. Al-Rasadi First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene Angiology 64 2013 287 292
3. D. Allard, S. Amsellem, M. Abifadel, M. Trillard, M. Devillers, G. Luc, M. Krempf, Y. Reznik, J.P. Girardet, A. Fredenrich, C. Junien, M. Varret, C. Boileau, P. Benlian, and J.P. Rabes Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia Hum. Mutat. 26 2005 497
4. M. Ando, T. Sanaka, and H. Nihei Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients J. Am. Soc. Nephrol. 10 1999 2177 2184
5. M. Arca, S. Natoli, F. Micheletta, S. Riggi, E. Di Angelantonio, A. Montali, T.M. Antonini, R. Antonini, U. Diczfalusy, and L. Iuliano Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy Free Radic. Biol. Med. 42 2007 698 705
6. M.A. Austin, C.M. Hutter, R.L. Zimmern, and S.E. Humphries Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review Am. J. Epidemiol. 160 2004 407 420
7. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
8. P. Barter, and H.N. Ginsberg Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia Am. J. Cardiol. 102 2008 1040 1045
9. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
10. K.E. Berge, L. Ose, and T.P. Leren Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy Arterioscler. Thromb. Vasc. Biol. 26 2006 1094 1100
11. Bezafibrate Infarction Prevention Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease Circulation 102 2000 21 27
12. A. Bhaskar, and A. Kumar Antihyperglycemic, antioxidant and hypolipidemic effect of Punica granatum L flower extract in streptozotocin induced diabetic rats Asian Pacific J. Tropical Biomed. 2 3 2012 S1764 S1769
13. M. Boberg, R. Angerbauer, P. Fey, W.K. Kanhai, W. Karl, A. Kern, J. Ploschke, and M. Radtke Metabolism of cerivastatin by human liver microsomes in vitro characterization of primary metabolic pathways and of cytochrome P450 isozymes involved Drug Metab. Dispos. 25 1997 321 331
14. A. Brautbar, and C.M. Ballantyne Pharmacological strategies for lowering LDL cholesterol: statins and beyond Nat. Rev. Cardiol. 8 2011 253 265
15. C. Brown, A. Windass, K. Bleasby, and B. Lauffart Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C Atheroscler. Suppl. 2 2001 90
16. J. Cameron, O.L. Holla, T. Ranheim, M.A. Kulseth, K.E. Berge, and T.P. Leren Effect of mutations in the PCSK9 gene on the cell surface LDL receptors Hum. Mol. Genet. 15 2006 1551 1558
17. N.F. Cariello, E.H. Romach, H.M. Colton, H. Ni, L. Yoon, J.G. Falls, W. Casey, D. Creech, S.P. Anderson, and G.R. Benavides Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver Toxicol. Sci. 88 2005 250 264
18. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J. Intern. Med. 258 2005 94 114
19. M.J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J. 31 2010 149 164
20. S.N. Chen, C.M. Ballantyne, A.M. Gotto Jr., Y. Tan, J.T. Willerson, and A.J. Marian A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis J. Am. Coll. Cardiol. 45 2005 1611 1619
21. Y. Chen, H. Ku, L. Zhao, D.C. Wheeler, L.-C. Li, Q. Li, Z. Varghese, J.F. Moorhead, S.H. Powis, and A. Huang Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation Arterioscler. Thromb. Vasc. Biol. 34 2014 365 376
22. P. Cheung, and L. Chan Nucleotide sequence of cloned cDNA of human apolipoprotein A-I Nucleic Acids Res. 11 1983 3703 3715
23. J.Y. Chung, J.Y. Cho, K.S. Yu, J.R. Kim, D.S. Oh, H.R. Jung, K.S. Lim, K.H. Moon, S.G. Shin, and I.J. Jang Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers Clin. Pharmacol. Ther. 78 2005 342 350
24. R. Citraro, E. Russo, F. Scicchitano, C.M. van Rijn, D. Cosco, C. Avagliano, R. Russo, G. D'Agostino, S. Petrosino, F. Guida, L. Gatta, G. van Luijtelaar, S. Maione, V. Di Marzo, A. Calignano, and G. De Sarro Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy Neuropharmacology 69 2013 115 126
25. V. Clavey, C. Copin, M. Mariotte, E. Bauge, G. Chinetti, J. Fruchart, J. Fruchart, J. Dallongeville, and B. Staels Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells Cell. Physiol. Biochem. 9 1999 139 149
26. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N. Engl. J. Med. 354 2006 1264 1272
27. Couvert, P., Giral, P., Dejager, S., Gu, J., Huby, T., Chapman, M.J., Bruckert, E., Carrié, A., 2008. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
28. P.A. Cox The ethnobotanical approach to drug discovery: strengths and limitations Ciba Found. Symp. 185 1994 25 36 (discussion 36-41)
29. P.A. Cox, and M.J. Balick The ethnobotanical approach to drug discovery Sci. Am. 270 1994 82 87
30. X. Cui [On comprehensive prescriptions of native herbs and its reference books cited] (Chi) Zhonghua yi shi za zhi 17 1987 234 240
31. J.W. Deng, I.-S. Song, H.J. Shin, C.-W. Yeo, D.-Y. Cho, J.-H. Shon, and J.-G. Shin The effect of SLCO1B1∗15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1∗15 Pharmacogenet. Genomics 18 2008 424 433
32. J.-P. Desager, Y. Horsmans, C. Vandenplas, and C. Harvengt Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days Atherosclerosis 124 1996 S65 S73
33. H. Duez, Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fievet, S.D. Wright, and B. Staels Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice J. Biol. Chem. 277 2002 48051 48057
34. A. Endo Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors Klin. Wochenschr. 66 1988 421 427
35. A. Endo The discovery and development of HMG-CoA reductase inhibitors J. Lipid. Res. 33 1992 1569 1582
36. D. Flavell, I.P. Torra, Y. Jamshidi, D. Evans, J. Diamond, R. Elkeles, S. Bujac, G. Miller, P. Talmud, and B. Staels Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects Diabetologia 43 2000 673 680
37. J.-C. Fruchart, and P. Duriez Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism Drugs Today 42 2006 39 64
38. H. Fujino, T. Saito, Si Ogawa, and J. Kojima Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase J. Pharm. Pharmacol. 57 2005 1305 1311
39. T. Furihata, N. Satoh, T. Ohishi, M. Ugajin, Y. Kameyama, K. Morimoto, S. Matsumoto, K. Yamashita, K. Kobayashi, and K. Chiba Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy Pharmacogenomics J. 9 2009 185 193
40. S.H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V.S. Kamanna, and M.L. Kashyap Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J. Lipid Res. 45 2004 1835 1845
41. C.K. Garcia, K. Wilund, M. Arca, G. Zuliani, R. Fellin, M. Maioli, S. Calandra, S. Bertolini, F. Cossu, N. Grishin, R. Barnes, J.C. Cohen, and H.H. Hobbs Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein Science 292 2001 1394 1398
42. R. Garuti, C. Jones, W.P. Li, P. Michaely, J. Herz, R.D. Gerard, J.C. Cohen, and H.H. Hobbs The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits J. Biol. Chem. 280 2005 40996 41004
43. D. Gaudet, J. Methot, S. Dery, D. Brisson, C. Essiembre, G. Tremblay, and K. Tremblay Efficacy and longterm safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial Gene. Ther. 20 2013 361 369
44. J.J. Genest Jr., S.S. Martin-Munley, J.R. McNamara, J.M. Ordovas, J. Jenner, R.H. Myers, S.R. Silberman, P.W. Wilson, D.N. Salem, and E.J. Schaefer Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 1992 2025 2033
45. A. Gille, E.T. Bodor, K. Ahmed, and S. Offermanns Nicotinic acid: pharmacological effects and mechanisms of action Annu. Rev. Pharmacol. Toxicol. 48 2008 79 106
46. M. Grube, K. Köck, S. Oswald, K. Draber, K. Meissner, L. Eckel, M. Böhm, S.B. Felix, S. Vogelgesang, and G. Jedlitschky Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart Clin. Pharmacol. Ther. 80 2006 607 620
47. R. Hajhosseiny, I. Sabir, K. Khavandi, and A.S. Wierzbicki The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future Clin. Pharmacol. Ther. 96 2014 64 73
48. R.H. Ho, R.G. Tirona, B.F. Leake, H. Glaeser, W. Lee, C.J. Lemke, Y. Wang, and R.B. Kim Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics Gastroenterology 130 2006 1793 1806
49. W.F. Ho, S.H. Koo, J.Y. Yee, and E.J. Lee Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore Drug Metab. Pharmacokinet. 23 2008 476 482
50. A. Iida, S. Saito, A. Sekine, C. Mishima, K. Kondo, Y. Kitamura, S. Harigae, S. Osawa, and Y. Nakamura Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins J. hum. Genet. 46 2001 668 683
51. Z. Israelian-Konaraki, and P.D. Reaven Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications Cardiology 103 2004 1 9
52. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
53. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
54. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L.Z. Benet, K.-F. Sewing, and U. Christians Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver Drug Metab. Dispos. 27 1999 173 179
55. S.R. Jada, S. Xiaochen, L.Y. Yan, X. Xiaoqiang, S. Lal, S.F. Zhou, L.L. Ooi, and B. Chowbay Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations Eur. J. Clin. Pharmacol. 63 2007 555 563
56. TA Jacobson, SB Glickstein, JD Rowe, and PN. Soni Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review J. Clin. Lipidol. 6 2012 5 18
57. M.R. Jones, and O.M. Nwose Role of colesevelam in combination lipid-lowering therapy Am. J. Cardiovasc. Drugs: Drugs Dev. Other Interv. 13 2013 315 323
58. T. Jørgensen, K. Borch-Johnsen, T.F. Thomsen, H. Ibsen, C. Glümer, and C. Pisinger A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1) Eur. J. Cardiovasc. Prev. Rehab. 10 2003 377 386
59. A. Kalliokoski, P.J. Neuvonen, and M. Niemi SLCO1B1 polymorphism and oral antidiabetic drugs Basic Clin. Pharmacol. Toxicol. 107 2010 775 781
60. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin Am. J. Cardiol. 101 2008 S20 S26
61. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1∗5, SLCO1B1∗15 and SLCO1B1∗15+ C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet. Genomics 15 2005 513 522
62. S.K. Karathanasis, J. McPherson, V.I. Zannis, and J.L. Breslow Linkage of human apolipoproteins A-I and C-III genes Nature 304 1983 371 373
63. D.A. Katz, R. Carr, D.R. Grimm, H. Xiong, R. Holley-Shanks, T. Mueller, B. Leake, Q. Wang, L. Han, and P.G. Wang Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics Clin. Pharmacol. Ther. 79 2006 186 196
64. B.G. Katzung, S.B. Masters, and A.J. Trevor Basic & Clinical Pharmacology 2001 Lange Medical Books/McGraw-Hill Toronto
65. R. Kerb Implications of genetic polymorphisms in drug transporters for pharmacotherapy Cancer Lett. 234 2006 4 33
66. T.J. Key, G.E. Fraser, M. Thorogood, P.N. Appleby, V. Beral, G. Reeves, M.L. Burr, J. Chang-Claude, R. Frentzel-Beyme, J.W. Kuzma, J. Mann, and K. McPherson Mortality in vegetarians and non-vegetarians: a collaborative analysis of 8300 deaths among 76,000 men and women in five prospective studies Public Health Nutr. 1 1998 33 41
67. S.H. Kim, M.K. Seo, M.H. Yoon, D.H. Choi, T.J. Hong, and H.S. Kim Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial Clin. Ther. 35 2013 77 86
68. S. Kitamura, K. Maeda, Y. Wang, and Y. Sugiyama Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin Drug Metab. Dispos. 36 2008 2014 2023
69. D. Kobayashi, T. Nozawa, K. Imai, J.-i. Nezu, A. Tsuji, and I. Tamai Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane J. Pharmacol. Exp. Ther. 306 2003 703 708
70. T.Y. Komarova, A.S. Golovina, N.A. Grudinina, F.M. Zakharova, V.A. Korneva, B.M. Lipovetsky, M.P. Serebrenitskaya, V.O. Konstantinov, V.B. Vasilyev, and M.Y. Mandelshtam New mutations in low-density lipoprotein receptor gene in familial hypercholesterolemia patients from Petrozavodsk Genetika 49 2013 773 777
71. K. Kopplow, K. Letschert, J. König, B. Walter, and D. Keppler Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells Mol. Pharmacol. 68 2005 1031 1038
72. P.M. Kris-Etherton, W.S. Harris, and L.J. Appel Omega-3 fatty acids and cardiovascular disease new recommendations from the American Heart Association Arterioscler. Thromb. Vasc. Biol. 23 2003 151 152
73. K.K. Kuo, S.J. Shin, Z.C. Chen, Y.H. Yang, J.F. Yang, and P.J. Hsiao Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease Br. J. Surg. 95 2008 1005 1011
74. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.-C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, and J. Shepherd Intensive lipid lowering with atorvastatin in patients with stable coronary disease N. Engl. J. Med. 352 2005 1425 1435
75. Lacquemant, C., Lepretre, F., Torra, I.P., Manraj, M., Charpentier, G., Ruiz, J., Staels, B., Froguel, P., 2008. Mutation screening of the PPAR agene in type 2 diabetes associated with coronary heart disease.
76. P.W. Ladenson, J.D. Kristensen, E.C. Ridgway, A.G. Olsson, B. Carlsson, I. Klein, J.D. Baxter, and B. Angelin Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N. Engl. J. Med. 362 2010 906 916
77. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscler., Thromb., Vasc. Bio. 30 2010 894 899
78. E. Lee, S. Ryan, B. Birmingham, J. Zalikowski, R. March, H. Ambrose, R. Moore, C. Lee, Y. Chen, and D. Schneck Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin. Pharmacol. Ther. 78 2005 330 341
79. S. Lee, T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz, P.M. Fernandez-Salguero, H. Westphal, and F.J. Gonzalez Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell. Biol. 15 1995 3012 3022
80. S.S. Lee, T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz, P.M. Fernandez-Salguero, H. Westphal, and F.J. Gonzalez Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell. Biol. 15 1995 3012 3022
81. Y.-F. Lei, J.-L. Chen, H. Wei, C.-M. Xiong, Y.-H. Zhang, and J.-L. Ruan Hypolipidemic and anti-inflammatory properties of Abacopterin A from Abacopteris penangiana n high-fat diet-induced hyperlipidemia mice Food Chem. Toxicol. 49 2011 3206 3210
82. G. Lambert, B. Sjouke, B. Choque, J.J. Kastelein, and G.K. Hovingh The PCSK9 decade J. Lipid. Res. 53 2012 2515 2524
83. M. Lukasova, J. Hanson, S. Tunaru, and S. Offermanns Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials Trends Pharmacol. Sci. 32 2011 700 707
84. D. Maccubbin, H. Bays, A. Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, and Q. Yu Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int. J. Clin. Pract. 62 2008 1959 1970
85. D. Maciejewski-Lenoir, J.G. Richman, Y. Hakak, I. Gaidarov, D.P. Behan, and D.T. Connolly Langerhans cells release prostaglandin D2 in response to nicotinic acid J. Investig. Dermatol. 126 2006 2637 2646
86. M. Man, M. Farmen, C. Dumaual, C.H. Teng, B. Moser, S. Irie, G.J. Noh, R. Njau, S. Close, S. Wise, and R. Hockett Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans J. Clin. Pharmacol. 50 2010 929 940
87. A.D. Marais, J.C. Firth, and D.J. Blom Homozygous familial hypercholesterolemia and its management 2004 Seminars in vascular medicine.Copyright© 2004 by Thieme Medical Publishers, Inc. 333 Seventh Avenue, New York, NY 10001, USA 43 50
88. M. Marrapodi, and J.Y. Chiang Peroxisome proliferator-activated receptor α (PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription J. Lipid Res. 41 2000 514 520
89. N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors and atherogenesis regulators of gene expression in vascular cells Circ. Res. 94 2004 1168 1178
90. R. Meneghini Iron homeostasis, oxidative stress, and DNA damage Free Radic. Biol. Med. 23 1997 783 792
91. P. Michaely, W.P. Li, R.G. Anderson, J.C. Cohen, and H.H. Hobbs The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits J. Biol. Chem. 279 2004 34023 34031
92. C. Michalski, Y. Cui, A.T. Nies, A.K. Nuessler, P. Neuhaus, U.M. Zanger, K. Klein, M. Eichelbaum, D. Keppler, and J. Konig A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter J. Biol. Chem. 277 2002 43058 43063
93. V. Mohan, R. Deepa, S.S. Rani, and G. Premalatha Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. The Chennai Urban Population Study (CUPS No. 5) J. Am. Coll. Cardiol. 38 2001 682 687
94. A. Morabia, E. Cayanis, M.C. Costanza, B.M. Ross, M.S. Bernstein, M.S. Flaherty, G.B. Alvin, K. Das, M.A. Morris, G.K. Penchaszadeh, P. Zhang, and T.C. Gilliam Association between lipoprotein lipase (LPL) gene and blood lipids: a common variant for a common trait? Genet. Epidemiol. 24 2003 309 321
95. A. Morabia, E. Cayanis, M.C. Costanza, B.M. Ross, M.S. Flaherty, G.B. Alvin, K. Das, and T.C. Gilliam Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors Hum. Mol. Genet. 12 2003 2733 2743
96. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa, and K. Chiba A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy Drug Metabol. Pharmacokinet. 19 2004 453 455
97. J.D. Morrow, W.G. Parsons III, and L.J. Roberts II Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid Prostaglandins 38 1989 263 274
98. R.Y. Mukhtar, J. Reid, and J.P. Reckless Pitavastatin Int. J. Clin. Pract. 59 2005 239 252
99. KG. Mustafa, B.A. Ganai, S. Akbar, MY Dar, and A Masood β-Cell protective efficacy, hypoglycemic and hypolipidemic effects of extracts of Achillea millifolium in diabetic rats Chinese J. Nat. Med. 10 3 2012 185 189
100. J. Mwinyi, K. Kopke, M. Schaefer, I. Roots, and T. Gerloff Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations Eur. J. Clin. Pharmacol. 64 2008 257 266
101. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda, and K. Nishimura Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J. Pharmacol. Exp. Ther. 297 2001 861 867
102. P. Nestel, H. Shige, S. Pomeroy, M. Cehun, M. Abbey, and D. Raederstorff The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans Am. J. Clin. Nutr. 76 2002 326 330
103. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund, J.T. Backman, R. Kerb, M. Schwab, P.J. Neuvonen, M. Eichelbaum, and K.T. Kivisto High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
104. E.J. Niesor, C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, and H. Matile Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport J. Lipid. Res. 51 2010 3443 3454
105. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin. Pharmacol. Ther. 73 2003 554 565
106. D.M. Niu, K.W. Chong, J.H. Hsu, T.J. Wu, H.C. Yu, C.H. Huang, M.Y. Lo, C.F. Kwok, L.E. Kratz, and L.T. Ho Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children J. Inherit. Metab. Dis. 33 2010 437 443
107. J. Noé, R. Portmann, M.-E. Brun, and C. Funk Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos. 35 2007 1308 1314
108. G.D. Norata, G. Tibolla, and A.L. Catapano Gene silencing approaches for the management of dyslipidaemia Trends Pharmacol. Sci. 34 2013 198 205
109. T. Nozawa, K. Imai, J. Nezu, A. Tsuji, and I. Tamai Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human J. Pharmacol. Exp. Ther. 308 2004 438 445
110. S. Oswald, J. König, D. Lütjohann, T. Giessmann, H.K. Kroemer, C. Rimmbach, D. Rosskopf, M.F. Fromm, and W. Siegmund Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1 Pharmacogenet. Genomics 18 2008 559 568
111. M. Paradise, C. Cooper, and G. Livingston Systematic review of the effect of education on survival in Alzheimers disease Int. Psychogeriatr. 21 2009 25 32
112. M.K. Pasanen, J.T. Backman, P.J. Neuvonen, and M. Niemi Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population Eur. J. Clin. Pharmacol. 62 2006 409 415
113. M.K. Pasanen, P.J. Neuvonen, and M. Niemi Global analysis of genetic variation in SLCO1B1 Pharmacogenomics 9 2008 19 33
114. U.K. Patil, S. Saraf, and V.K. Dixit Hypolipidemic activity of seeds of Cassia tora Linn J. Ethnopharmacol. 90 2004 249 252
115. X. Prieur, H. Coste, and J.C. Rodríguez The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-α and contains a novel farnesoid X-activated receptor response element J. Biol. Chem. 278 2003 25468 25480
116. M. Puligheddu, G. Pillolla, M. Melis, S. Lecca, F. Marrosu, M.G. De Montis, S. Scheggi, G. Carta, E. Murru, S. Aroni, A.L. Muntoni, and M. Pistis PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings PloS One 8 2013 e64541
117. S. Ramachandran, A. Rajasekaran, and K. Manisenthilkumar Investigation of hypoglycemic, hypolipidemic and antioxidant activities of aqueous extract of Terminalia paniculata bark in diabetic rats Asian Pac. J. Trop. Biomed. 2 2012 262 268
118. K.K. Ray, C.P. Cannon, C.H. McCabe, R. Cairns, A.M. Tonkin, F.M. Sacks, G. Jackson, and E. Braunwald Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromesResults from the PROVE IT-TIMI 22 trial J. Am. Coll. Cardiol. 46 2005 1405 1410
119. J.K. Reddy, S.K. Goel, M.R. Nemali, J.J. Carrino, T.G. Laffler, M.K. Reddy, S.J. Sperbeck, T. Osumi, T. Hashimoto, and N.D. Lalwani Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators Proc. Natl. Acad. Sci. 83 1986 1747 1751
120. R.S. Rosenson Antiatherothrombotic effects of nicotinic acid Atherosclerosis 171 2003 87 96
121. I. Rudkowska, and P.J. Jones Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease Nutr. Rev. 66 2008 343 348
122. K.A. Rye, and P.J. Barter Regulation of high-density lipoprotein metabolism Circ. Res. 114 2014 143 156
123. N.S. Sabeva, J. Liu, and G.A. Graf The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease Curr. Opin. Endocrinol. Diabetes Obes. 16 2009 172 177
124. S. Sadigh-Eteghad, M. Talebi, and M. Farhoudi Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimers disease. A meta-analysis Neurosciences 17 2012 321 326
125. D. Sanoudou, A. Duka, K. Drosatos, K.C. Hayes, and V.I. Zannis Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice Pharmacogenomics J. 10 2010 165 179
126. M. Sasaki, H. Suzuki, K. Ito, T. Abe, and Y. Sugiyama Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2) J. Biol. Chem. 277 2002 6497 6503
127. D.W. Schneck, B.K. Birmingham, J.A. Zalikowski, P.D. Mitchell, Y. Wang, P.D. Martin, K.C. Lasseter, C.D. Brown, A.S. Windass, and A. Raza The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin. Pharmacol. Ther. 75 2004 455 463
128. K. Schoonjans, B. Staels, P. Grimaldi, and J. Auwerx Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation Eur. J. Biochem. 216 1993 615 622
129. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N.B. Wolf, F. Dorje, M.F. Fromm, and J. Konig The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3 Drug Metab. Dispos.: Biol. Fate Chem. 35 2007 779 786
130. Y. Shitara, M. Hirano, H. Sato, and Y. Sugiyama Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J. Pharmacol. Exp. Ther. 311 2004 228 236
131. R. Shukla, S. Gupta, J.K. Gambhir, K.M. Prabhu, and P.S. Murthy Antioxidant effect of aqueous extract of the bark of Ficus bengalensis in hypercholesterolaemic rabbits J. Ethnopharmacol. 92 2004 47 51
132. S.G. Simonson, A. Raza, P.D. Martin, P.D. Mitchell, J.A. Jarcho, C.D. Brown, A.S. Windass, and D.W. Schneck Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin. Pharmacol. Ther. 76 2004 167 177
133. M.I. Sirinian, F. Belleudi, F. Campagna, M. Ceridono, T. Garofalo, F. Quagliarini, R. Verna, S. Calandra, S. Bertolini, M. Sorice, M.R. Torrisi, and M. Arca Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes J. Biol. Chem. 280 2005 38416 38423
134. A.K. Soutar, and R.P. Naoumova Autosomal recessive hypercholesterolemia Semin. Vasc. Med. 4 2004 241 248
135. A.K. Soutar, R.P. Naoumova, and L.M. Traub Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 23 2003 1963 1970
136. T. Sparso, M.S. Hussain, G. Andersen, I. Hainerova, K. Borch-Johnsen, T. Jorgensen, T. Hansen, and O. Pedersen Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people Mol. Genet. Metab. 90 2007 205 209
137. A.C. Spósito, A. Mansur, R. Maranhão, C. Rodrigues-Sobrinho, O. Coelho, and J. Ramires Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects Braz. J. Med. Biol. Res. 34 2001 177 182
138. D.L. Sprecher Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review Am. J. Cardiol. 86 2000 46 50
139. B. Staels, and J. Auwerx Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models Development 115 1992 1035 1043
140. B. Staels, A. Van Tol, G. Verhoeven, and J. Auwerx Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner Endocrinology 126 1990 2153 2163
141. B. Staels, J. Peinado-Onsurbe, and J. Auwerx Down-regulation of hepatic lipase gene expression and activity by fenofibrate Biochim. Biophys. Acta (BBA) - Lipids Lipid Metab. 1123 1992 227 230
142. B. Staels, A. van Tol, T. Andreu, and J. Auwerx Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat Arterioscler. Thromb. Vasc. Biol. 12 1992 286 294
143. B. Staels, A. Van Tol, G. Skretting, and J. Auwerx Lecithin: cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates J. Lipid Res. 33 1992 727 735
144. B. Staels, N. Vu-Dac, V. Kosykh, R. Saladin, J. Fruchart, J. Dallongeville, and J. Auwerx Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates J. Clin. Investig. 95 1995 705
145. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
146. B. Staels, M. Maes, and A. Zambon Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nature clinical practice Cardiovasc. Med. 5 2008 542 553
147. S. Stender, R. Frikke-Schmidt, B.G. Nordestgaard, and A. Tybjaerg-Hansen Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population Hepatology 53 2011 640 648
148. A.C. Strang, R.J. Bisoendial, R.S. Kootte, D.M. Schulte, G.M. Dallinga-Thie, J.H. Levels, M. Kok, K. Vos, S.W. Tas, U.J. Tietge, N. Muller, M. Laudes, D.M. Gerlag, E.S. Stroes, and P.P. Tak Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis Atherosclerosis 229 2013 174 181
149. W.K. Sumanasekera, E.S. Tien, R. Turpey, J.P. Vanden Heuvel, and G.H. Perdew Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2 J. Biol. Chem. 278 2003 4467 4473
150. E. Tai, S. Demissie, L. Cupples, D. Corella, P. Wilson, E. Schaefer, and J. Ordovas Association between the PPARA L162V polymorphism and plasma lipid levels the framingham offspring study Arterioscler. Thromb. Vasc. Biol. 22 2002 805 810
151. T. Tanaka, J.M. Ordovas, J. Delgado-Lista, F. Perez-Jimenez, C. Marin, P. Perez-Martinez, P. Gomez, and J. Lopez-Miranda Peroxisome proliferator-activated receptor α polymorphisms and postprandial lipemia in healthy men J. Lipid Res. 48 2007 1402 1408
152. Z. Tang, H. Gao, S. Wang, S. Wen, and S. Qin Hypolipidemic and antioxidant properties of a polysaccharide fraction from Enteromorpha prolifera Int. J. Biol. Macromol. 58 2013 186 189
153. I. Tatsuno, Y. Saito, K. Kudou, and J. Ootake Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study J. Clin. Lipidol. 7 2013 615 625
154. A.J. Taylor, H.J. Lee, and L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr. Med. Res. Opin. 22 2006 2243 2250
155. A.J. Taylor, T.C. Villines, E.J. Stanek, P.J. Devine, L. Griffen, M. Miller, N.J. Weissman, and M. Turco Extended-release niacin or ezetimibe and carotid intima-media thickness N. Engl. J. Med. 361 2009 2113 2122
156. G.J. Ten Kate, L.A. Neefjes, A. Dedic, K. Nieman, J.G. Langendonk, A.J. Galema-Boers, J. Roeters van Lennep, A. Moelker, G.P. Krestin, E.J. Sijbrands, and P.J. de Feyter The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia Atherosclerosis 227 2013 334 341
157. A. Tenenbaum, and E.Z. Fisman Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction Cardiovasc. Diabetol. 11 2012 125
158. A. Tenenbaum, M. Motro, E.Z. Fisman, E. Schwammenthal, Y. Adler, I. Goldenberg, J. Leor, V. Boyko, L. Mandelzweig, and S. Behar Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease Circulation 109 2004 2197 2202
159. A. Tenenbaum, M. Motro, E.Z. Fisman, D. Tanne, V. Boyko, and S. Behar Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch. Intern. Med. 165 2005 1154 1160
160. J. Thomas, K.S. Bramlett, C. Montrose, P. Foxworthy, P.I. Eacho, D. McCann, and L.F. Michael A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor J. Biol. Chem. 278 4 2003 2403 2410
161. J.F. Thompson, M. Man, K.J. Johnson, L.S. Wood, M.E. Lira, D.B. Lloyd, P. Banerjee, P.M. Milos, S.P. Myrand, J. Paulauskis, M.A. Milad, and W.J. Sasiela An association study of 43 SNPs in 16 candidate genes with atorvastatin response Pharmacogenomics J. 5 2005 352 358
162. R.G. Tirona, B.F. Leake, G. Merino, and R.B. Kim Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J. Biol. Chem. 276 2001 35669 35675
163. R.G. Tirona, B.F. Leake, A.W. Wolkoff, and R.B. Kim Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J. Pharmacol. Exp. Ther. 304 2003 223 228
164. P.P. Toth, T.D. Dayspring, and G.S. Pokrywka Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids Curr. Atheroscler. Rep. 11 2009 71 79
165. K. Tripathi Essential of Medical Pharmacology 1998 Jaypee Brothers medical Publishers (P) Ltd Delhi
166. E.S. van Aalst-Cohen, A.C. Jansen, S. de Jongh, P.R. de Sauvage Nolting, and J.J. Kastelein Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia Semin. Vasc. Med. 4 2004 31 41
167. P. Verma, S. Deshpande, Y. Kamtham, and L. Vaidya Hypolipidemic and antihyperlipidemic effects from an aqueous extract of Pachyptera hymenaea (DC.) leaves in rats Food Chem. 132 2012 1251 1257
168. J. Versmissen, D.M. Oosterveer, M. Yazdanpanah, M. Mulder, A. Dehghan, J.C. Defesche, J.J. Kastelein, and E.J. Sijbrands A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients Eur. Heart J. 32 2011 469 475
169. M.-C. Vohl, P. Lepage, D. Gaudet, C.G. Brewer, C. Bétard, P. Perron, G. Houde, C. Cellier, J.M. Faith, and J.-P. Després Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperapobetalipoproteinemia J. Lipid Res. 41 2000 945 952
170. N. Vu-Dac, K. Schoonjans, B. Laine, J.-C. Fruchart, J. Auwerx, and B. Staels Negative regulation of the human apolipoprotein AI promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element J. Biol. Chem. 269 1994 31012 31018
171. N. Vu-Dac, P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L.A. Pennacchio, E.M. Rubin, J. Fruchart-Najib, and J.C. Fruchart Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators J. Biol. Chem. 278 2003 17982 17985
172. J.R. Walters, and S.S. Pattni Managing bile acid diarrhoea Ther. Adv. Gastroenterol. 3 2010 349 357
173. D. Williams, and J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin. Pharmacokinet. 41 2002 343 370
174. K.R. Wilund, M. Yi, F. Campagna, M. Arca, G. Zuliani, R. Fellin, Y.K. Ho, J.V. Garcia, H.H. Hobbs, and J.C. Cohen Molecular mechanisms of autosomal recessive hypercholesterolemia Hum. Mol. Genet. 11 2002 3019 3030
175. MY Wei, and TA. Jacobson Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis Curr. Atheroscler. Rep. 13 2011 474 483
176. A.S. Wierzbicki, T. Hardman, and W.T. Prince Future challenges for microsomal transport protein inhibitors Curr. Vas. Pharmacol. 7 2009 277 286
177. A.S. Wierzbicki, T.C. Hardman, and A. Viljoen Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia Expert Opin. Investig. Drugs 21 2012 667 676
178. B.J. Wu, L. Yan, F. Charlton, P. Witting, P.J. Barter, and K.-A. Rye Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids Arterioscler. Thromb. Vasc. Biol. 30 2010 968 l975
179. F. Yadetie, A. Laegreid, I. Bakke, W. Kusnierczyk, J. Komorowski, H.L. Waldum, and A.K. Sandvik Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate Physiol. Genomics 15 2004 9 19
180. H. Ye, Q. Zhao, Y. Huang, L. Wang, H. Liu, C. Wang, D. Dai, L. Xu, M. Ye, and S. Duan Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671 polymorphism and coronary heart disease BioMed Res. Int. 2014 564940
181. X.-Q. Zha, J.-J. Xiao, H.-N. Zhang, J.-H. Wang, L.-H. Pan, X.-F. Yang, and J.-P. Luo Polysaccharides in Laminaria japonica (LP): extraction, physicochemical properties and their hypolipidemic activities in diet-induced mouse model of atherosclerosis Food Chem. 134 2012 244 252